Join us for a poster highlight of the top abstracts from the Clinical Practice SIG.&nbsp;<br />
&nbsp;

The following poster categories will be in the Poster Hall:
<ul>
<li>MASLD/MASH - Experimental: Basic</li>
<li>Hepatitis B</li>
<li>Hepatitis C</li>
<li>MASLD/MASH - Experimental: Clinical</li>
<li>Alcohol-Associated Liver Diseases: Clinical and Experimental</li>
</ul>

Presenters explore new practice paradigms for optimizing liver tarnsplant acccess and examine effective strategies for dissemination of knowledge regarding the benefit of living donor liver transplant (LDLT) through directed, nondirected, and paired donation. Other topics include the role of machine perfusion in improving transplant access, outreach hepatology and transplant clinics, telehepatology, and the role of minimally-invasive surgical techniques in the growth of LDLT programs.

Presenters focus on empowering patients to effectively navigate the health care system. Topics include debunking common myths, utilizing practical tools, and understanding the differences between alternative, complementary, and integrative medicine.

Panelists highlight the perspectives of providers and people living with hepatitis B regarding strategies to assess and address patient-reported outcomes, and cultivate shared decision-making that is informed by scientific evidence, provider expertise, and patient preferences. The diverse panel includes representatives of nonprofit organizations, health systems, academic institutions, and patient advocacy groups. A question-and-answer period follows speaker presentations.

CDC's Division of Viral Hepatitis Director Carolyn Wester will discuss the on-going work at DVH and the division's role in the White House Hepatitis C Elimination plan.

This session will highlight evolving approaches to second-line treatment in Primary Biliary Cholangitis (PBC) through a case-based discussion. It will provide practical insights and foster a dynamic exchange between leading hepatologists.<br />
<br />
Industry Supporter:&nbsp;Ipsen

Our newest survey highlights what many already know: managing SLD isn&rsquo;t just about liver health. Barriers like transportation, finances, isolation, and mental health challenges play a big role in how people experience their condition. Join us for an honest, community conversation about these realities, and hear about programs and resources designed to help you take care of both your health and your well-being.<br />
<br />
<strong>Zoom:</strong> <a href="https://us02web.zoom.us/webinar/register/WN_bPc7LXWuQcuhltX1HFZ1zw">htt…;

&quot;Sober&quot; can mean more than life without alcohol&mdash;it can also mean approaching life with clarity, balance, and thoughtful awareness. This conversation explores the many meanings of sobriety&mdash;clarity, calm, and conscious living&mdash;and how those qualities help us navigate a world that feels increasingly loud and unsettled. Together, we&rsquo;ll talk about what&rsquo;s within our control, what&rsquo;s not, and how to stay steady, compassionate, and connected without diving into divisive topics&mdash;focusing instead on how the world around us shapes our inner resilience.<br />
<br />
<strong>Zoom: </strong><a href="https://us02web.zoom.us/meeting/register/s49_sh31TWOuhSOUQR7Iug">https:…;

This program is designed to explore the recent FDA announcement and <em>HEPATOLOGY</em>&nbsp;publication regarding the role of non-invasive tests (NITs) in MASH clinical trials. The session will review the regulatory perspectives, scientific evidence, and clinical implications of these developments. It will also provide a forum for open dialogue and audience engagement, highlighting both opportunities and challenges for integrating NITs into practice and research. Attendees will leave with a clearer understanding of how these updates may shape the future landscape of hepatology and drug development.